Invitrogen Corporation Announces Strategic Collaboration with Tecan

Invitrogen Corporation and Tecan are entering into a collaboration agreement to validate the compatibility of Invitrogen’s reagents with Tecan’s microplate detection instruments.

Invitrogen’s drug discovery products will be validated on selected Tecan microplate readers and instruments, starting with the Infinite® series readers.

Initial certifications will focus on Invitrogen’s assay systems for key target classes, such as LanthaScreen™ TR-FRET for protein kinases, GeneBLAzer® reporter-gene technology for G protein-coupled receptors and Adapta™, a new TR-FRET assay system for lipid kinases. This collaboration will allow Tecan and Invitrogen to develop and promote joint applications for the drug discovery market.

“Through this partnership with Tecan, we will be able to provide integrated instrumentation and reagent solutions to the research community. Previously, this has been a major source of frustration when researchers find that selected technologies are not compatible with the instrument and visa versa,” said John Printen, Invitrogen director of cell signaling. “Our goal is to enable researchers to select the right Invitrogen assay system for optimum performance on Tecan instruments.”